



Rüdiger P Laubender

Contact

Rüdiger P Laubender

Publications (7)

Beigel F, Brand S, Seiderer J, Göke B, Laubender R, Van Steen K, John J, Breiteneicher S, Tillack C, Schnitzler F, Steinborn A, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. *Pharmacoepidemiol Drug Saf* 2014; 23:735-44.

Tillack C, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schaubert J, Wollenberg A, Maier H, Wetzke M, Ehmann L, Friedrich M, Laubender R, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- γ -expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. *Gut* 2013; 63:567-77.

Beigel F, Ochsenkühn T, Seiderer J, Göke B, Weidinger M, Breiteneicher S, Schnitzler F, Tillack C, Laubender R, Löhner B, Brand S. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. *Digestion* 2011; 85:47-54.

Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender R, Auernhammer C. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. *Endocr Relat Cancer* 2011; 18:277-85.

Glas J, Czamara D, Diegelmann J, Lohse P, Ochsenkühn T, Göke B, Müller-Myhsok B, Weidinger M, Laubender R, Olszak T, Jürgens M, Beigel F, Pfennig S, Tillack C, Seiderer J, Brand S. The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants. *PLoS one* 2010; 5:e14466.

Jürgens M, Herrmann K, Lohse P, Göke B, Kreis M, Schnitzler F, Weidinger M, Beigel F, Tillack C, Pfennig S, Wagner J, Wetzke M, Glas J, Seiderer J, Laubender R, Brand S, Ochsenkühn T. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype. *J Gastroenterol* 2010; 45:721-31.

Jürgens M, Ochsenkühn T, Glas J, Göke B, Lohse P, Tillack C, Schnitzler F, Stallhofer J, Pfennig S, Beigel F, Wetzke M, Wagner J, Seiderer J, Weidinger M, Hartl F, Laubender R, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. *Am J Gastroenterol* 2010; 105:1811-9.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch